DARZALEX® Redefining Approaches in Early-Line Multiple Myeloma Treatment

NDMM TRANSPLANT-INELIGIBLE PATIENTS

DARZALEX® + VMP

(bortezomib + melphalan +
prednisone)

ALCYONE TRIAL

NDMM = newly diagnosed multiple myeloma.

AFTER 1 PRIOR THERAPY

DARZALEX® + Rd

(lenalidomide +
dexamethasone)

POLLUX TRIAL

DARZALEX® + Vd

(bortezomib +
dexamethasone)

CASTOR TRIAL

AFTER 2 PRIOR THERAPIES*

DARZALEX® + Pd

(pomalidomide +
dexamethasone)

EQUULEUS TRIAL

*Prior therapies included lenalidomide and a proteasome inhibitor (PI).

AFTER 3 PRIOR THERAPIES

DARZALEX®
Monotherapy

SIRIUS TRIAL

Prior therapies included a PI and an immunomodulatory agent or patients were double-refractory to a PI and an immunomodulatory agent.

Extensive clinical experience in multiple myeloma1

>52,000 Patients Treated
Estimated Worldwide Since Approval2

1166 Patients Treated With DARZALEX® in Clinical Trials1

6 Registrational Trials in Multiple Myeloma1§

 

As of June 2018. Estimate based on projected patients, calculations of demand, and duration of treatment.

§Includes 3 large, phase 3 clinical trials.

DARZALEX® is a CD38-targeted cytolytic antibody indicated1:

  • in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant
  • in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy
  • in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI)
  • as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent

Revlimid® and Pomalyst® are registered trademarks of Celgene Corporation.
Velcade® is a registered trademark of Millennium Pharmaceuticals, Inc.